Coronavirus: Moderna CEO on timeline for phase one vaccine results
CNBC's Meg Tirrell talks with Moderna CEO Stephane Bancel and Regeneron CEO Leonard Schleifer about the race to a coronavirus treatment during CNBC's Healthy Returns event.
Moderna said on Tuesday the U.S. Food and Drug Administration granted “fast track” designation to its experimental coronavirus vaccine, a move that speeds up the regulatory review process.
Moderna has been racing to develop a safe and effective vaccine against the novel coronavirus that has killed more than 285,000 people globally.
A vaccine or treatment that gets the “fast track” designation is eligible for the agency’s “priority review” status, under which the FDA aims to take a decision on approving the drug within six months.
More than 100 potential COVID-19 vaccines are being developed, including several in clinical trials, but the World Health Organization in April had warned that a vaccine would take at least 12 months.
For more coronavirus live updates:
https://www.cnbc.com/2020/05/12/coronavirus-latest-updates.html
For access to live and exclusive video from CNBC subscribe to CNBC PRO:
https://cnb.cx/2JdMwO7
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBC TV
Видео Coronavirus: Moderna CEO on timeline for phase one vaccine results канала CNBC Television
Moderna said on Tuesday the U.S. Food and Drug Administration granted “fast track” designation to its experimental coronavirus vaccine, a move that speeds up the regulatory review process.
Moderna has been racing to develop a safe and effective vaccine against the novel coronavirus that has killed more than 285,000 people globally.
A vaccine or treatment that gets the “fast track” designation is eligible for the agency’s “priority review” status, under which the FDA aims to take a decision on approving the drug within six months.
More than 100 potential COVID-19 vaccines are being developed, including several in clinical trials, but the World Health Organization in April had warned that a vaccine would take at least 12 months.
For more coronavirus live updates:
https://www.cnbc.com/2020/05/12/coronavirus-latest-updates.html
For access to live and exclusive video from CNBC subscribe to CNBC PRO:
https://cnb.cx/2JdMwO7
» Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision
» Subscribe to CNBC: https://cnb.cx/SubscribeCNBC
» Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
Connect with CNBC News Online
Get the latest news: http://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: https://cnb.cx/FollowCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
#CNBC
#CNBC TV
Видео Coronavirus: Moderna CEO on timeline for phase one vaccine results канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Scientist says a coronavirus vaccine in just 12 months is 'fake news' | 60 Minutes AustraliaModerna CEO on partnering with Lonza, logistical challenges of scaling a vaccineWhy We Might Not Need A Vaccine for COVID-19 | This MorningWe will see above-trend economic growth in 2022: Hightower's Stephanie LinkGilead's moving quickly with FDA for approval of coronavirus drug remdesivir: CEOThe search for COVID-19 vaccine continues, Belgian scientishts are hopeful to find a cureBread crumbs from chip sector are bullish, sending tech stocks higher: Wedbush's Dan IvesCOVID-19 Affects Some More Than Others, Why?Demand for PCR, at-home Covid tests surges as omicron fears spreadThe COVID Vaccine: When Will It Be Ready?Omicron variant has dominated playing field, will likely overtake delta: Dr. Syra MadadCEO Pascal Soriot on COVID-19 vaccine - CNNVaccine volunteer on his second injectionCOVID-19: The race for a vaccine and the pandemic’s impact on the future of public healthInovio surges on early coronavirus vaccine testing data in animalsYale professor breaks down Moderna's timeline for a COVID-19 vaccineFrom mayors to musicians: Here's why workers want to get paid in cryptoCoronavirus: Top Labs See Real Progress On Immunity, Vaccine | NBC Nightly NewsOxford Vaccine, Moderna, CDC, Test Sensitivity and SpecificityDoctor Explains How Fast a Covid-19 Vaccine Could Be Created | Cause + Control | WIRED